Active learning improved whole-cell antibiotic screening and validation
A closed-loop active-learning campaign for Borrelia burgdorferi whole-cell screening increased the experimental hit rate five-fold, from 0.2% in investigator-selected plates to 1.0% in the AL-guided campaign. The same study separately reports prospective in-silico selection of diverse compounds across bacterial species, with 11.0% experimental validation of predicted hits and 53-fold enrichment over investigator-directed screening; those validated compounds showed the intended narrow-spectrum B. burgdorferi activity. These are assay and screening results, not clinical efficacy.
Technology: Active learning using a directed message-passing neural network and evidential Dirichlet head
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: In a closed-loop Borrelia burgdorferi campaign, active-learning-guided selection produced a 1.0% experimental screening hit rate versus 0.2% in investigator-selected plates. A separate prospective in-silico selection across bacterial species achieved 11.0% experimental validation of predicted hits (53-fold enrichment over investigator-directed screening); the paper reports intended narrow-spectrum activity for B. burgdorferi.
- Still unknown: Preprint evidence is not independent replication or clinical testing. The cross-species hit-validation experiment is distinct from the closed-loop Borrelia hit-rate comparison. Direct full page retrieval was blocked; checked material was the primary indexed preprint and archived primary article text.
- AI role: A directed message-passing neural network with an evidential Dirichlet head supported active-learning compound selection for whole-cell inhibition testing; selected compounds were then experimentally screened.
Evidence sources: https://www.biorxiv.org/content/10.64898/2026.07.04.736489v1 · https://pmc.ncbi.nlm.nih.gov/articles/PMC13344992/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Primary bioRxiv indexed text, PubMed metadata/abstract and PMC indexed full-text excerpt; direct bioRxiv and PMC page loads were blocked..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.